Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy. Letter
- PMID: 35648648
- DOI: 10.1097/JU.0000000000002790
Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy. Letter
Comment in
-
Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy. Reply.J Urol. 2022 Sep;208(3):567. doi: 10.1097/JU.0000000000002791. Epub 2022 Jun 1. J Urol. 2022. PMID: 35648647 No abstract available.
Comment on
-
Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy.J Urol. 2022 Jun;207(6):1295-1301. doi: 10.1097/JU.0000000000002437. Epub 2022 Jan 20. J Urol. 2022. PMID: 35050717 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
